Valuation: FluoGuide A/S

Capitalization 391M 60.97M 52.31M 48.71M 45.33M 84.59M 5.5B 91.19M 560M 220M 2.63B 229M 224M 9.65B P/E ratio 2025 *
-10.1x
P/E ratio 2026 * -8.06x
Enterprise value 339M 52.85M 45.35M 42.23M 39.3M 73.33M 4.77B 79.05M 486M 191M 2.28B 198M 194M 8.36B EV / Sales 2025 *
-
EV / Sales 2026 * -
Free-Float
62.92%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-1.15%
1 week+1.48%
1 month-7.55%
3 months-22.40%
6 months-14.25%
More quotes
1 week 33.6
Extreme 33.6
35.5
1 month 33.1
Extreme 33.1
37.9
Current year 33.1
Extreme 33.1
36.9
1 year 29.1
Extreme 29.1
57
3 years 29.1
Extreme 29.1
119.8
5 years 29.1
Extreme 29.1
160
10 years 4.1
Extreme 4.1
160
More quotes
Manager TitleAgeSince
Chief Executive Officer 62 31/12/2017
Chief Tech/Sci/R&D Officer 63 31/12/2019
Director of Finance/CFO 61 01/02/2023
Director TitleAgeSince
Director/Board Member 63 29/01/2018
Chairman 66 08/02/2021
Director/Board Member 55 31/12/2020
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-1.15%+1.48%-23.18%-37.52% 61.58M
+2.18%+0.64%+11.51%+5.66% 228B
-2.94%-8.02%+1.09%+108.14% 199B
+0.72%+0.73%-0.14%-13.69% 166B
-0.95%-5.26%-2.29%+103.00% 140B
+0.66%+1.60%-7.85%-6.31% 60.69B
-1.81%-3.09%+15.72%+4.25% 48.65B
-0.12%-0.88%+2.15%-5.72% 41.48B
+0.19%-0.90%+1.02%+34.20% 38.61B
+1.61%+4.25%+13.08%+14.81% 37.1B
Average -0.13%-1.71%+1.11%+20.68% 95.98B
Weighted average by Cap. -0.06%-2.30%+3.54%+37.90%
See all sector performances

Financials

2025 *2026 *
Net sales - -
Net income -39M -6.08M -5.22M -4.86M -4.52M -8.44M -549M -9.1M -55.89M -21.99M -263M -22.82M -22.35M -963M -60M -9.36M -8.03M -7.48M -6.96M -12.99M -845M -14M -85.98M -33.82M -404M -35.1M -34.38M -1.48B
Net Debt -52M -8.11M -6.96M -6.48M -6.03M -11.26M -732M -12.13M -74.52M -29.31M -350M -30.42M -29.8M -1.28B -82M -12.79M -10.98M -10.22M -9.51M -17.75M -1.15B -19.13M -118M -46.23M -552M -47.98M -46.99M -2.02B
More financial data * Estimated data
Logo FluoGuide A/S
FluoGuide A/S is a Denmark-based biotechnology company focused on developing drugs for maximizing surgical outcomes by making cancer fluorescent. The Company is a provider of solutions for maximizing surgical outcome through intelligent targeting. FluoGuide develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The Company’s main product, FG001, is designed using FluoGuide’s uPAR technology platform to improve surgical precision by illuminating cancer cells intraoperatively. FluoGuide explores FG001 in three other severe cancer indications, namely lung, head & neck, meningioma and low grade glioma.
Employees
8
More about the company
Date Price Change Volume
14/01/26 34.30 kr -1.15% 6,321
13/01/26 34.70 kr +1.46% 2,206
12/01/26 34.20 kr -2.29% 7,948
09/01/26 35.00 kr +0.57% 8,882
08/01/26 34.80 kr +2.96% 8,275

Delayed Quote Nasdaq Stockholm, January 14, 2026 at 05:00 pm

More quotes

Annual profits - Rate of surprise